Close
Smartlab Europe
Inizio Ignite

Bristol-Myers Squibb to Announce Results for Second Quarter 2016 on July 28

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

- Advertisement -

Bristol-Myers Squibb Company will announce results for the second quarter of 2016 on Thursday, July 28, 2016. During a conference call at 10:30 a.m. EDT on July 28, company executives will review financial information and will address inquiries from investors and analysts.

Investors and the general public are invited to listen to a live webcast of the call athttp://investor.bms.com or by dialing in the U.S. toll free 877-201-0168 or international 647-788-4901, confirmation code: 91350399. Materials related to the call will be available at the same website prior to the conference call. A replay of the call will be available beginning at 1:30 p.m. EDT on July 28 through 11:59 p.m. EDT on August 11, 2016. The replay will also be available through http://investor.bms.com or by dialing in the U.S. toll free 855-859-2056 or international 404-537-3406, confirmation code: 91350399.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Contact:

Bristol-Myers Squibb Company
Media: 
Ken Dominski, 609-252-5251
ken.dominski@bms.com

or

Lisa McCormick Lavery, 609-252-7602
lisa.mccormicklavery@bms.com

or
 
Investors:
John Elicker, 609-252-4611
john.elicker@bms.com

or

Ranya Dajani, 609-252-5330
ranya.dajani@bms.com

or

Bill Szablewski, 609-252-5894
william.szablewski@bms.com
 

Latest stories

Related stories

How APAC Biotech Plans to Turn 2026 Trends into Innovation While Managing Risk?

Asia-Pacific’s biotechnology landscape is not just growing it is...

Laboratory Equipment Outsourcing Through CDMOs: Strategic and Cost Implications

Outsourcing laboratory infrastructure to CDMOs offers pharma companies critical agility, transforming fixed capital costs into flexible operational expenses while accessing cutting-edge technology like Cryo-EM.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »